FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

BackgroundPancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic cancer.MethodsPAK1 expression was measured in pancreatic cancer specimens by immunohistochemistry and in pancreatic cancer cell lines by western blotting. The effect of inhibition of PAK1 by either shRNA knock-down (KD), or by a selective inhibitor, FRAX597, alone or in combination with gemcitabine, on cell proliferation and migration/invasion was measured by thymidine uptake and Boyden chamber assays, respectively. The effect on tumour growth and survival was assessed in orthotopic murine models.ResultsPAK1 was expressed in all human pancreatic cancer samples tested, an7d was upregulated in all pancreatic cancer cell lines tested. PAK1 KD inhibited pancreatic cancer cell growth and survival, and increased sensitivity to gemcitabine treatment. AKT activity and HIF1α expression were also inhibited. FRAX597 inhibited pancreatic cancer cell proliferation, survival, and migration/invasion. When combined with gemcitabine, FRAX597 synergistically inhibited pancreatic cancer proliferation in vitro and inhibited tumour growth in vivo.ConclusionsThese results implicate PAK1 as a regulator of pancreatic cancer cell growth and survival. Combination of a PAK1 inhibitor such as FRAX597 with cytotoxic chemotherapy deserves further study as a novel therapeutic approach to pancreatic cancer treatment.

• Publication year

  2016

• Venue

  BMC Cancer

• Publication date

  2016-01-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s12885-016-2057-zPMID 26774265PMCID 4715347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of p21-activated kinases in pancreatic cancer.

  2015cited by this paper
• Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.

  2014cited by this paper
• Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer

  2014cited by this paper
• p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines

  2014cited by this paper
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

  2014cited by this paper
• The impact of hypoxia in pancreatic cancer invasion and metastasis

  2014cited by this paper
• Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.

  2014cited by this paper
• Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis

  2014cited by this paper
• P21 activated kinases

  2014cited by this paper
• P21-activated kinase 1 promotes colorectal cancer survival by up-regulation of hypoxia-inducible factor-1α.

  2013cited by this paper
• FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas*

  2013influential reference
• Comparison of Two Syngeneic Orthotopic Murine Models of Pancreatic Adenocarcinoma

  2013cited by this paper
• Genomic sequencing of key genes in mouse pancreatic cancer cells.

  2012cited by this paper
• PAK signaling in cancer

  2012cited by this paper
• Pancreatic cancer: Overview of descriptive epidemiology

  2012cited by this paper
• p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.

  2012cited by this paper
• Molecular biology of pancreatic cancer.

  2011cited by this paper
• MUC13 Mucin Augments Pancreatic Tumorigenesis

  2011cited by this paper
• P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.

  2010cited by this paper
• Phenotype and Genotype of Pancreatic Cancer Cell Lines

  2010cited by this paper
• Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host

  2010cited by this paper
• High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.

  2008cited by this paper
• Tumorigenesis and Neoplastic Progression Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia

  2007cited by this paper
• The molecular biology of pancreatic cancer.

  2007cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Sugars to signals: emerging roles of PAK1 in re-wiring glucose metabolism in cancers

  2025cites this paper
• The Important Role of p21-Activated Kinases in Pancreatic Exocrine Function

  2025cites this paper
• METTL3/IGF2BP3 axis promotes gemcitabine resistance of pancreatic cancer cells through regulating USP33-mediated PAK1 deubiquitination and degradation

  2025cites this paper
• Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer

  2025cites this paper
• [Computer-aided prediction and molecular mechanism investigation of active components in compound Kushen injection inhibiting p21-activated kinase 1].

  2024cites this paper
• PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.

  2024cites this paper
• Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance

  2023cites this paper
• PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response

  2023cites this paper
• The role of miRNA-26a-5p and target gene socs1a in flutolanil induced hepatotoxicity of zebrafish at environmental relevant levels.

  2023cites this paper
• Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma

  2023cites this paper
• Targeting p21-activated kinase 1 for development of a novel anti-arrhythmic drug class

  2023cites this paper
• The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma.

  2022cites this paper
• Enhanced CNN Model for Pancreatic Ductal Adenocarcinoma Classification Based on Proteomic Data

  2022cites this paper
• The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review

  2022cites this paper
• p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond

  2022cites this paper
• P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer

  2022cites this paper
• Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1

  2022cites this paper
• p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma

  2021cites this paper
• Complementary omics strategies to dissect p53 signaling networks under nutrient stress

  2021influential citation
• Proteogenomic characterization of pancreatic ductal adenocarcinoma.

  2021cites this paper
• The Role of p21-Activated Kinases in Cancer and Beyond: Where Are We Heading?

  2021cites this paper
• A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine

  2021cites this paper
• Targeting Rho GTPase Signaling Networks in Cancer

  2020cites this paper
• Thifluzamide induces the toxic effects on zebrafish (Danio rerio) via inhibition of succinate dehydrogenase (SDH).

  2020cites this paper
• Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases

  2020cites this paper
• Systemic analysis of the expression and prognostic significance of PAKs in breast cancer.

  2020cites this paper
• Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.

  2020cites this paper
• RAC1 mutation is not a predictive biomarker for PI3'-kinase- selective pathway-targeted therapy.

  2020cites this paper
• Identification of a novel PAK1 inhibitor to treat pancreatic cancer

  2019cites this paper
• P21 activated kinase signaling in cancer.

  2019cites this paper
• PAK1 Expression in Pancreatic Cancer: Clinicopathological Characteristics and Prognostic Significance

  2019cites this paper
• Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.

  2019cites this paper
• EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis.

  2019cites this paper
• PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines.

  2019cites this paper
• PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression

  2019cites this paper
• Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.

  2019cites this paper
• PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients.

  2019cites this paper
• Inhibitors of the p21 Activated Kinases

  2018cites this paper
• The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines

  2018cites this paper
• Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates

  2018cites this paper
• Upregulation of P21-Activated Kinase 1 (PAK1)/CREB Axis in Squamous Non-Small Cell Lung Carcinoma

  2018cites this paper
• p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

  2018cites this paper
• Nutrient scavenging in cancer

  2018cites this paper
• Overexpression of PAK1 Correlates with Aberrant Expression of EMT Markers and Poor Prognosis in Non-Small Cell Lung Cancer

  2017cites this paper
• Paving the Rho in cancer metastasis: Rho GTPases and beyond.

  2017cites this paper
• Inhibiting Kinases in the CNS

  2017cites this paper
• From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.

  2017cites this paper
• Inhibition of group 1 p21‐activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer

  2017cites this paper
• Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.

  2017cites this paper
• Biological nanoparticles carrying the Hmda-7 gene are effective in inhibiting pancreatic cancer in vitro and in vivo

  2017cites this paper
• Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?

  2016cites this paper
• Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation

  2016cites this paper
• Targeting p21 activated kinase 1 (Pak1) to PAKup Pancreatic Cancer

  2016influential citation